Association between performance measures and clinical outcomes in patients with heart failure in China: Results from

Shiyue Zheng1, Li Li2, Chao Jiang1

  • 1Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China.

Clinical Cardiology
|February 20, 2024
PubMed

Insights

Adherence to heart failure (HF) performance measures in China is low, but higher compliance is linked to reduced mortality. Improving care quality for HF patients is crucial.

Area of Science:

  • Cardiology
  • Healthcare Quality
  • Public Health

Background:

  • Significant variation exists in hospital care quality across China.
  • Studies on heart failure (HF) performance measures and patient prognosis are limited.

Purpose of the Study:

  • To investigate the association between adherence to performance measures and clinical outcomes in Chinese HF patients.
  • To clarify the impact of performance measures on HF patient prognosis in China.

Main Methods:

  • Analysis of 4497 HF patients from the Heart Failure Registry of Patient Outcomes study.
  • Categorization of patients into four groups based on composite performance scores.
  • Utilized multiple imputation and Cox proportional-hazard regression models.

Main Results:

  • Only 12.5% of patients met the top 25% performance measures; 33.5% met the bottom 25%.
  • 1-year mortality was 22.2%, with higher rates in the lowest performance group (27.0% vs. 16.3%).
  • Meeting top performance measures correlated with a lower 1-year mortality rate (aHR: 0.78, 95% CI: 0.61-0.98).

Conclusions:

  • A dose-response relationship exists between performance measure compliance and mortality in HF patients.
  • Increased adherence to performance measures is associated with decreased HF patient mortality.
  • Urgent improvements in the quality of care for HF patients in China are recommended.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
122
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431